Intellia Therapeutics (NASDAQ:NTLA) Price Target Raised to $30.00 at HC Wainwright

Intellia Therapeutics (NASDAQ:NTLA) had its target price raised by HC Wainwright from $25.00 to $30.00 in a report published on Tuesday,Benzinga reports. The firm currently has a buy rating on the stock.

Other research analysts have also recently issued research reports about the company. Bank of America reissued a “neutral” rating on shares of Intellia Therapeutics in a research note on Monday. Wall Street Zen cut shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, January 18th. Wolfe Research reiterated a “peer perform” rating on shares of Intellia Therapeutics in a research report on Wednesday, November 12th. Wells Fargo & Company lowered their target price on shares of Intellia Therapeutics from $17.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Friday, November 7th. Finally, William Blair upgraded shares of Intellia Therapeutics from a “market perform” rating to an “outperform” rating in a report on Monday. Ten investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $19.14.

Intellia Therapeutics Price Performance

NTLA opened at $13.60 on Tuesday. The firm’s fifty day moving average price is $12.09 and its 200 day moving average price is $13.10. The stock has a market capitalization of $1.61 billion, a PE ratio of -3.55 and a beta of 2.10. Intellia Therapeutics has a 12-month low of $5.90 and a 12-month high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, February 26th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($0.99) by $0.16. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. The firm had revenue of $23.02 million during the quarter, compared to analyst estimates of $12.17 million. The firm’s revenue for the quarter was up 78.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.27) earnings per share. On average, equities research analysts forecast that Intellia Therapeutics will post -5.07 earnings per share for the current fiscal year.

Insider Activity

In other Intellia Therapeutics news, EVP Birgit C. Schultes sold 8,508 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $78,358.68. Following the sale, the executive vice president directly owned 98,533 shares of the company’s stock, valued at $907,488.93. The trade was a 7.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP James Basta sold 10,397 shares of the stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $95,756.37. Following the completion of the sale, the executive vice president directly owned 101,528 shares of the company’s stock, valued at approximately $935,072.88. This represents a 9.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 53,051 shares of company stock valued at $488,600 over the last three months. Insiders own 3.10% of the company’s stock.

Institutional Trading of Intellia Therapeutics

Hedge funds have recently made changes to their positions in the stock. Schroder Investment Management Group increased its position in Intellia Therapeutics by 1,593.4% in the 2nd quarter. Schroder Investment Management Group now owns 406,425 shares of the company’s stock worth $3,812,000 after purchasing an additional 382,425 shares during the last quarter. Marex Group plc acquired a new stake in Intellia Therapeutics in the second quarter valued at approximately $5,849,000. JPMorgan Chase & Co. grew its position in Intellia Therapeutics by 73.0% in the second quarter. JPMorgan Chase & Co. now owns 940,483 shares of the company’s stock worth $8,822,000 after acquiring an additional 396,858 shares in the last quarter. AXQ Capital LP acquired a new position in shares of Intellia Therapeutics during the 2nd quarter worth $285,000. Finally, SG Americas Securities LLC increased its stake in shares of Intellia Therapeutics by 239.7% during the 3rd quarter. SG Americas Securities LLC now owns 131,070 shares of the company’s stock worth $2,264,000 after purchasing an additional 92,485 shares during the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics News Roundup

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA removed the clinical hold on Intellia’s MAGNITUDE Phase 3 / heart‑disease gene therapy program — a major regulatory clearing event that had already pushed the stock higher. US FDA lifts clinical hold on Intellia’s heart disease gene therapy trial
• Positive Sentiment: Several brokers raised ratings/price targets (William Blair upgraded to Outperform; HC Wainwright, Citizens JMP and Leerink raised price targets), signaling improving analyst sentiment and potential re‑rating upside. Intellia Therapeutics (NASDAQ:NTLA) Upgraded by William Blair to “Outperform” Rating Analyst price target changes
• Positive Sentiment: Notable institutional/big‑name interest: Cathie Wood’s ARK (coverage article) is buying depressed growth names, which can attract investor attention and flows into beaten‑down biotech names. Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
• Neutral Sentiment: Company presented longer‑term clinical data for lonvo‑z at AAAAI (three‑year follow‑up and patient‑focused research) — supportive but not an immediate regulatory catalyst. Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z)
• Neutral Sentiment: Smaller price‑target increases from RBC and Wells Fargo to $15 provide modest near‑term support but signal only limited upside vs. some higher analyst targets. RBC & Wells Fargo PT raises
• Negative Sentiment: Canaccord trimmed its price target from $54 to $48 (still a Buy) — a reduction in optimism that could weigh on sentiment given prior higher targets and the stock’s recent run. Canaccord lowers price target

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.